Nucleic acid delivery and nanoparticle design for COVID vaccines
Download43577_2021_169_ReferencePDF.pdf (870.5Kb)
Publisher Policy
Publisher Policy
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Terms of use
Metadata
Show full item recordAbstract
Abstract
Nucleic acid therapeutics offer a new paradigm to rapidly respond to global health problems. The versatility of nucleic acids, especially in RNA therapies, provides the ability to tune levels of specific protein expression, achieving downregulation through short interfering RNA (siRNA) or upregulation by messenger RNA (mRNA) administration. Recent advances in the development of delivery vehicles, including nonviral nanoparticles are crucial to overcome the innate barriers to nucleic acid delivery. Toward this end, current clinical approaches have utilized mRNA and lipid nanoparticles (LNPs) to address the COVID-19 pandemic through novel vaccine strategies, producing efficacious vaccines within one year of sequencing the SARS-CoV-2 genome. Here, we review fundamental concepts required to achieve successful nucleic acid delivery, including the design of LNP systems optimized for mRNA vaccine applications.
Graphic abstract
Date issued
2021-09Department
Massachusetts Institute of Technology. Department of ChemistryJournal
MRS Bulletin
Publisher
Springer Science and Business Media LLC
Citation
Andresen, Jason L. and Fenton, Owen S. 2021. "Nucleic acid delivery and nanoparticle design for COVID vaccines."
Version: Author's final manuscript
ISSN
0883-7694
1938-1425